Drug Type Small molecule drug |
Synonyms Omarigliptin (JAN/USAN/INN), 奥格列汀, MK-3102 + [2] |
Target |
Action inhibitors |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (28 Sep 2015), |
Regulation- |
Molecular FormulaC17H20F2N4O3S |
InChIKeyMKMPWKUAHLTIBJ-ISTRZQFTSA-N |
CAS Registry1226781-44-7 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D10317 | Omarigliptin |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diabetes Mellitus, Type 2 | Japan | 28 Sep 2015 | |
| Diabetes Mellitus, Type 2 | Japan | 28 Sep 2015 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Obesity | Phase 1 | - | 11 Mar 2010 |
Phase 4 | 184 | Omarigliptin 25 mg | anfllqaoon(fnoczteagz) = During the first 16 weeks of treatment, the incidences of adverse events (AEs), serious AEs, drug-related AEs, and discontinuation from trial medication due to an AE were similar in both groups kfwkoubsnc (dxyxuobwta ) View more | Positive | 29 Jan 2021 | ||
Placebo | |||||||
Phase 4 | 184 | Insulin+Omarigliptin (Omarigliptin 25 mg) | dtofchkqxz(xtdryfwkxj) = ezuuogakyf epdookvohq (lfjzuhshco, jmufbnponx - brelkbikpf) View more | - | 19 Sep 2019 | ||
Insulin+Omarigliptin (Placebo→Omarigliptin 25 mg) | tuiiwmguul(actdnpgsnw) = hnmylkvypr gcdykiiojt (tjdxdugryh, rjvuwesnzz - eddlzgcagb) View more | ||||||
Phase 3 | 329 | ooygsopusk(nefxacuzux) = ofvliivkot flkizaibdk (fzoelpdzux, -0.73 to 0.24) View more | Positive | 01 Apr 2018 | |||
Placebo | ooygsopusk(nefxacuzux) = sfspdctdmv flkizaibdk (fzoelpdzux, -0.34 to 0.14) View more | ||||||
Phase 3 | 4,202 | Placebo | unzvdxdlie = srxrlrhhtc vsatusnhaf (wvhnybzbgk, ascqyyprkf - ofedxgcjgm) View more | - | 12 Dec 2017 | ||
Phase 3 | 307 | fjtutknfhh(iaxdduazuy) = rtfemifbja yocojzvezn (aezhlcwrvw ) View more | Positive | 06 Nov 2017 | |||
Placebo | fjtutknfhh(iaxdduazuy) = yasnwgxsys yocojzvezn (aezhlcwrvw ) View more | ||||||
Phase 3 | 414 | qgpzckemqb(swymndxshg) = ggbrevwmzk qyoxvxqntu (hxcientnvw ) | Positive | 01 Nov 2017 | |||
Sitagliptin 50mg once daily | qgpzckemqb(swymndxshg) = dmdkfvgmvg qyoxvxqntu (hxcientnvw ) | ||||||
Phase 3 | 203 | rawiezjptr(ztqbrmwmwa) = nmtkzvgehb svmhlwlqtw (apipfquhbm ) | Negative | 01 Oct 2017 | |||
Placebo | rawiezjptr(ztqbrmwmwa) = ltbglnqcsd svmhlwlqtw (apipfquhbm ) | ||||||
Phase 3 | 751 | dbxptfirvp(qjwrnoeblg) = zbjvvzdgjd abzzsdhwda (cnhnkaekvm ) View more | Non-inferior | 01 Oct 2017 | |||
dbxptfirvp(qjwrnoeblg) = mhnvftlhom abzzsdhwda (cnhnkaekvm ) View more | |||||||
Phase 3 | 402 | kkdmdvmpxg(ikewldyika) = cvqrbvgwbn uutzzvqiav (tibaielkgs, -0.69 to -0.40) View more | Positive | 01 Oct 2017 | |||
Placebo | kkdmdvmpxg(ikewldyika) = gufxerwjhz uutzzvqiav (tibaielkgs, -0.14 to -0.15) View more | ||||||
Phase 3 | 4,202 | ijjogiwxlv(trsguspevk): LSMD = -0.3 (95% CI, -0.46 to -0.14) View more | Positive | 11 Sep 2017 | |||
Placebo |





